Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HTR7 | P34969 | 7/20 | 0.60 |
| ▸ | HTR1A | P08908 | 6/20 | 0.60 |
| ▸ | ADRB1 | P08588 | 4/20 | 0.57 |
| ▸ | HTR3E | A5X5Y0 | 3/20 | 0.57 |
| ▸ | HTR3B | O95264 | 3/20 | 0.57 |
| ▸ | HTR3A | P46098 | 3/20 | 0.57 |
| ▸ | HTR3D | Q70Z44 | 3/20 | 0.57 |
| ▸ | HTR3C | Q8WXA8 | 3/20 | 0.57 |
| ▸ | SIGMAR1 | Q99720 | 3/20 | 0.57 |
| ▸ | HTR2C | P28335 | 3/20 | 0.57 |
| ▸ | THRB | P10828 | 2/20 | 0.57 |
| ▸ | HTR6 | P50406 | 2/20 | 0.57 |
| ▸ | TP53 | P04637 | 1/20 | 0.57 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.57 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.57 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.57 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.57 |
| ▸ | HTR2A | P28223 | 1/20 | 0.57 |
| ▸ | SLC6A4 | P31645 | 1/20 | 0.57 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.57 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Hydrochloric Acid SCHEMBL6504153 | 0.98 | HTR7 (0.58) | HTR7HTR1AADRB1HTR3EHTR3B | |
| Hydrochloric Acid SCHEMBL6409641 | 0.98 | HTR7 (0.58) | HTR7HTR1AADRB1HTR3EHTR3B | |
| SCHEMBL13118658 | 0.94 | HTR7 (0.67) | HTR7HTR1AADRB1HTR3EHTR3B | |
| SCHEMBL5686209 | 0.87 | HTR7 (0.57) | HTR7HTR1AADRB1HTR3EHTR3B | |
| Tert-Butyl Formate SCHEMBL27634126 | 0.84 | ADRB1 (0.47) | HTR7HTR1AADRB1HTR3EHTR3B | |
| SCHEMBL28216220 | 0.84 | AGXT (0.57) | HTR7DRD2DRD3ALDH1A1MAPT | |
| SCHEMBL3960459 | 0.84 | AGXT (0.62) | HTR7DRD2DRD3ALDH1A1MAPT | |
| SCHEMBL301359 | 0.83 | ADRB1 (0.62) | HTR7HTR1AADRB1HTR3EHTR3B | |
| SCHEMBL7415117 | 0.83 | HTR7 (0.62) | HTR7HTR1AADRB1HTR3EHTR3B | |
| SCHEMBL27475990 | 0.83 | HTR7 (0.60) | HTR7HTR1AADRB1HTR3EHTR3B |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 26 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3002278-B1 | GUANIDINE COMPOUND | ASTELLAS PHARMA INC (JP) | 2017-04-19 | — | — | EP | disclosed |
| WO-2017040449-A1 | TRIAZOLOPYRIDINE INHIBITORS OF MYELOPEROXIDASE | BRISTOL-MYERS SQUIBB COMPANY (US) | 2017-03-09 | — | — | WO | disclosed |
| US-9556160-B2 | Guanidine compound | ASTELLAS PHARMA INC. (JP) | 2017-01-31 | — | — | US | disclosed |
| US-9556160-B2 | Guanidine compound | ASTELLAS PHARMA INC. (JP) | 2017-01-31 | — | — | US | disclosed |
| EP-2695881-B1 | GUANIDINE COMPOUND | ASTELLAS PHARMA INC (JP) | 2016-04-27 | — | — | EP | disclosed |
| EP-3002278-A1 | GUANIDINE COMPOUND | Astellas Pharma Inc. (JP) | 2016-04-06 | — | — | EP | disclosed |
| US-20150203480-A1 | GUANIDINE COMPOUND | ASTELLAS PHARMA INC. (JP) | 2015-07-23 | — | — | US | disclosed |
| US-20150203480-A1 | GUANIDINE COMPOUND | ASTELLAS PHARMA INC. (JP) | 2015-07-23 | — | — | US | disclosed |
| US-9051283-B2 | Guanidine compound | ASTELLAS PHARMA INC. (JP) | 2015-06-09 | — | — | US | disclosed |
| US-9051283-B2 | Guanidine compound | ASTELLAS PHARMA INC. (JP) | 2015-06-09 | — | — | US | disclosed |
| WO-2008009741-A1 | NOVEL CHROMENE AND THIOCHROMENE CARBOXAMIDE DERIVATIVES, METHODS FOR PREPARING SAME AND THERAPEUTIC APPLICATIONS OF SAME | PIERRE FABRE MEDICAMENT (FR) | 2008-01-24 | — | — | WO | disclosed |
| WO-2008009741-A1 | NOVEL CHROMENE AND THIOCHROMENE CARBOXAMIDE DERIVATIVES, METHODS FOR PREPARING SAME AND THERAPEUTIC APPLICATIONS OF SAME | PIERRE FABRE MEDICAMENT (FR) | 2008-01-24 | — | — | WO | disclosed |
| EP-1651602-A2 | ARYL HETEROAROMATIC PRODUCTS, COMPOSITIONS COMPRISING THE SAME AND USE THEREOF | Aventis Pharma S.A. (FR) | 2006-05-03 | — | — | EP | disclosed |
| EP-1641765-A1 | ARYL-HETEROAROMATIC PRODUCTS, COMPOSITIONS CONTAINING SAME AND USE THEREOF | Aventis Pharma S.A. (FR) | 2006-04-05 | — | — | EP | disclosed |
| EP-1590329-A1 | N-ARYL HETEROAROMATIC PRODUCTS, COMPOSITIONS CONTAINING SAME AND USE THEREOF | Aventis Pharma S.A. (FR) | 2005-11-02 | — | — | EP | disclosed |
| WO-2005009947-A2 | ARYL HETEROAROMATIC PRODUCTS, COMPOSITIONS COMPRISING THE SAME AND USE THEREOF | AVENTIS PHARMA S.A. (FR) | 2005-02-03 | — | — | WO | disclosed |
| WO-2004108685-A1 | ARYL-HETEROAROMATIC PRODUCTS, COMPOSITIONS CONTAINING SAME AND USE THEREOF | AVENTIS PHARMA S.A. (FR) | 2004-12-16 | — | — | WO | disclosed |
| WO-2004078732-A1 | N-ARYL HETEROAROMATIC PRODUCTS, COMPOSITIONS CONTAINING SAME AND USE THEREOF | AVENTIS PHARMA S.A. (FR) | 2004-09-16 | — | — | WO | disclosed |
| EP-1112251-A1 | AZETIDINE DERIVATIVES, PREPARATION AND MEDICINES CONTAINING THEM | Aventis Pharma S.A. (FR) | 2001-07-04 | — | — | EP | disclosed |
| WO-2000015609-A1 | AZETIDINE DERIVATIVES, PREPARATION AND MEDICINES CONTAINING THEM | AVENTIS PHARMA S.A. (FR) | 2000-03-23 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20150203480-A1 | GUANIDINE COMPOUND | GUCY1A1, VAPA, VAPB | HTR7 4205/4885HTR1A 3680/4885ADRB1 494/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.